Filings Radar

SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.

BIOVIE INC. (BIVIW)

CIK 0001580149 1 material event

Insider activity (SEC Form 4)

Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.

Open-market · last 30 days: 4 buyers bought $49K 0 sellers sold $0
Open-market · last 90 days: 4 buyers bought $49K 0 sellers sold $0
InsiderRoleDateTransactionSharesValue
Chappell Amy Suzon Director 2026-08-28 Open-market buy 727 $2K
KIM JOANNE WENDY Chief Financial Officer 2026-08-28 Open-market buy 2500 $5K
Palumbo Joseph M Chief Medical Officer 2026-08-28 Open-market buy 4843 $10K
DO CUONG V President & CEO, Director 2026-08-27 Open-market buy 15210 $32K
DO CUONG V President & CEO, Director 2025-08-07 Open-market buy 5000 —
Most recent 5 reported transactions. Open-market buys (P) and sells (S) are the deliberate ones; grants and option exercises are compensation. Not investment advice.

Operational Other

8-K filed 2026-08-06 confidence 75% Item 7.01

BioVie announced topline results from its Phase 2 SUNRISE-PD trial of bezisterim in early-stage Parkinson's disease, showing statistically significant improvements on motor and non-motor symptoms, favorable biomarker changes, and a safety profile comparable to placebo. This is a material clinical development milestone for a clinical-stage biopharmaceutical company that would affect investor assessment of the drug candidate's viability and the company's prospects, but it does not fit the earnings_release category (which typically applies to financial results) nor any other specific event type. The disclosure is clearly operational/strategic in nature—a significant clinical trial result that informs future development decisions.

View raw filing on EDGAR →